C

    CureVac NV (CVAC)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $4.66
    +0.00 (+0.00%)

    Market Cap: $1.05B

    Last updated: Aug 31, 2026 at 5:00 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    64%(14/22)
    Avg Surprise
    -12.28%
    Streak
    2 Q
    PeriodReportedEst.SurpriseB/MYoY
    Mar 26
    Reported Apr 29
    		$0.00N/A+100.00%Beat+100.0%
    Sep 25
    Reported Nov 24
    		$-0.07N/A+53.33%Beat-104.7%
    Jun 25
    Reported Aug 15
    		$-0.26$-0.05-466.45%Miss+25.3%
    Mar 25
    Reported Apr 10
    		$-0.16$-0.19+17.65%Beat+60.1%
    Dec 24
    Reported Dec 31
    		$-0.14$-0.09-54.19%Miss+66.7%
    Sep 24
    Reported Nov 12
    		$1.50$0.61+145.90%Beat+781.8%
    Jun 24
    Reported Aug 15
    		$-0.35$-0.26-33.92%Miss-16.1%
    Mar 24
    Reported Apr 24
    		$-0.39$-0.18-116.67%Miss-44.4%
    Dec 23
    Reported Mar 12
    		$-0.42$-0.20-110.00%Miss+36.4%
    Sep 23
    Reported Nov 14
    		$-0.22$-0.23+4.35%Beat+12.0%
    Jun 23
    Reported Aug 17
    		$-0.30$-0.24-25.00%Miss+3.2%
    Mar 23
    Reported Apr 27
    		$-0.27$-0.34+20.59%Beat-237.5%
    Dec 22
    Reported Dec 31
    		$-0.66$-0.34-94.12%Miss+14.3%
    Sep 22
    Reported Nov 16
    		$-0.25$-0.27+7.41%Beat+69.7%
    Jun 22
    Reported Aug 18
    		$-0.31$-0.26-19.23%Miss+6.1%
    Mar 22
    Reported Apr 28
    		$-0.08N/A+84.00%Beat+78.9%
    Sep 21
    Reported Nov 18
    		$-0.77$-0.85+9.41%Beat-220.8%
    Jun 21
    Reported Aug 16
    		$-0.82$-0.85+2.94%Beat-184.5%
    Mar 21
    Reported Apr 15
    		$-0.33$-0.51+35.29%Beat-
    Dec 20
    Reported Mar 31
    		$-0.38$-0.61+37.70%Beat-
    Sep 20
    Reported Nov 30
    		$-0.24$-0.35+31.43%Beat-
    Jun 20
    Reported Aug 14
    		$-0.29N/A+99.47%Beat-

    Key Metrics

    Valuation
    P/E Ratio-6.64EV/EBITDA2.82x
    Price/FCF-7.85xFCF Yield-12.73%
    Profitability
    Profit Margin182.10%Operating Margin573.00%
    ROE40.20%ROICN/A
    Financial Health
    Debt/EquityN/AInterest CoverageN/A
    Current Ratio3.70xQuick Ratio3.69x
    Trading Statistics
    Beta1.84Avg VolumeN/A
    52-Week High$5.5552-Week Low$4.00

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$4.66
    SMA 20$4.66
    SMA 50$4.66
    SMA 200$4.79
    EMA 10$4.66
    EMA 20$4.66
    EMA 50$4.66
    EMA 200$4.68

    MACD

    Line: N/ASignal: N/AHist: N/A

    ADX

    ADX: 7.1+DI: 25.8-DI: 29.7

    Aroon & PSAR

    Aroon Up100.0
    Aroon Down100.0
    PSAR$4.66

    Bollinger Bands

    Upper Band$4.66
    Lower Band$4.66
    %B PositionN/A
    Band Width0.50

    RSI (14-Day)

    Neutral
    48.0

    Momentum Oscillators

    Stoch %KN/A
    Stoch %DN/A
    Williams %RN/A
    ROC (10d)N/A
    MomentumN/A
    CCI (20d)N/A
    MFI (14d)N/A

    Volatility Measures

    ATR (14d)N/A(0.0%)
    StdDev (20d)N/A
    Hist VolN/A

    Volume Flow

    VWAP$4.66
    OBV11.5M
    AD Line3.7M
    CMF (20d)N/A

    Volume Metrics

    Avg Vol (20d)N/A
    Vol RatioN/A
    VWMA (20d)N/A

    Pivot Points

    R3$4.66
    R2$4.66
    R1$4.66
    Pivot Point$4.66
    S1$4.66
    S2$4.66
    S3$4.66

    Advanced Oscillators

    TSI-2.35
    Ultimate OscN/A
    KSTN/A

    Financial Data

    QuarterSep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023Jun 2023Mar 2023Dec 2022
    Total Revenue$493.90M$1.25M$893,000$14.47M$493.90M$14.44M$12.37M$22.57M$16.48M$7.58M$7.13M$11.69M
    Cost of Revenue$-21,931,000$2.21M$875,000$1.49M$21.93M$40.72M$41.69M$53.60M$24.28M$25.85M$20.64M$80.00M
    Gross Profit$472.97M$-968,000$18,000$12.98M$471.97M$-26,287,000$-29,316,000$-31,030,000$-7,798,000$-18,275,000$-13,506,000$-68,312,000
    Operating Expenses$-32,612,000$60.78M$54.74M$55.46M$103.59M$47.33M$44.92M$111.68M$46.71M$53.70M$47.16M$53.67M
    R&D$49.98M$34.88M$37.59M$44.14M$49.98M$31.09M$27.82M$33.36M$27.25M$30.87M$24.25M$27.62M
    SG&A$25.43M$21.39M$16.41M$16.34M$14.06M$13.37M$16.69M$21.68M$15.84M$18.98M$19.60M$23.57M
    Operating Income$368.38M$-61,746,000$-54,727,000$-40,988,000$368.38M$-73,620,000$-73,317,000$-89,109,000$-54,036,000$-71,801,000$-60,355,000$-121,510,000
    Interest Income$3.29M$2.34M$3.40M$3.72M$2.33M$2.53M$3.77M$2.80M$9.45M$6.20M$3.89M$6.61M
    Interest Expense$6.92M$565,000$333,000$636,000$141,000$155,000$340,000$4.33M$4.08M$1.78M$951,000$630,000
    Income Before Tax$370.57M$-59,966,000$-51,655,000$-38,561,000$370.57M$-71,243,000$-69,887,000$-86,488,000$-48,675,000$-67,387,000$-57,418,000$-128,750,000
    Income Tax Expense$-32,529,000$-406,000$429,000$0$32.53M$1.30M$666,000$0$6,000$26,000$1,000$34,000
    Net Income$338.04M$-59,560,000$-52,084,000$-32,761,000$338.04M$-72,543,000$-70,553,000$-86,653,000$-48,681,000$-67,414,000$-57,419,000$-128,784,000
    EBITDAN/A$-54,993,000$-46,745,000N/A$375.23M$-65,962,000$-64,417,986N/A$-38,308,458$-59,968,000$-50,526,173$-126,381,000
    EBITN/A$-59,401,000$-51,322,000N/A$370.71M$-71,088,000$-69,547,000N/A$-44,590,000$-65,758,237$-56,467,000$-121,510,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about CVAC

    News

    ROUNDUP: Klarheit über Biontech-Standorte bis Ende September ()

    Biontech plans to decide by the end of September on the future of its production sites in Germany (Idar-Oberstein, Marburg) and Singapore, as well as Curevac sites, which are threatened with closure. These measures, potentially affecting up to 1,860 jobs (including 820 at Curevac), are driven by underutilization, overcapacities, cost savings, and a strategic shift towards oncology research after a sharp decline in COVID-19 vaccine demand. As part of this restructuring, Biontech is also divesting its subsidiary JPT Peptide Technologies GmbH, with Dubag Group acquiring the company and its 130 employees.

    aktiencheck.de•8/27/26•
    Neutral

    CureVac NV outlines its mRNA ambitions as vaccine work continues

    CureVac NV is a biotechnology company focused on messenger RNA (mRNA) therapeutics and vaccines, developing RNA-based medicines for infectious diseases and cancer. The company's strategy revolves around using mRNA to instruct the body to produce specific proteins for immune responses, employing proprietary RNA design and manufacturing to compete in the intense biotech landscape. As with many biotech stocks, investor perception for CureVac NV is closely tied to its clinical development progress and regulatory milestones.

    AD HOC NEWS•7/7/26•
    Somewhat-Bullish

    If You Invested $1,000 in Curevac B.V. (CVAC)

    This article analyzes the historical performance of investing $1,000 in Curevac B.V. (CVAC) over various periods, showing significant losses since its trading started in 2020. It also provides an overview of Curevac B.V., detailing its focus on mRNA-based medicines, its therapeutic pipelines in oncology and prophylactic vaccines, and its ongoing acquisition by BioNTech. The company's financial structure, collaborations, and technological innovations are also discussed.

    Stock Titan•7/4/26•
    Somewhat-Bearish

    CureVac NV (CVAC) Institutional Confidence

    This article provides an "Institutional Confidence" score for CureVac NV (CVAC) from TradingKey, indicating a previous score of 3.00 with no change. It lists significant institutional shareholder activity, noting both the Bill & Melinda Gates Foundation and BlackRock Institutional Trust Company, N.A. have reduced their holdings by 100.00%. The data on institutional confidence was last updated on January 5, 2026.

    TradingKey•6/18/26•
    Neutral

    CureVac NV (CVAC) Dividends & Stock Splits: Historical Payouts and Event Timeline

    This article provides an overview of CureVac NV's (CVAC) dividend history and stock split information. It indicates that the company has distributed $0.00 in dividends over the past five years and has no recorded stock split events. The page also presents current stock data such as market cap and P/E ratio.

    TradingKey•6/18/26•
    Neutral

    Frequently Asked Questions About CVAC

    Does CVAC pay dividends?
    CureVac NV (CVAC) does not currently pay a regular dividend.
    What is CVAC's market cap?
    CureVac NV (CVAC) has a market capitalization of $1.05B with a current stock price of $4.66.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In